Annual report [Section 13 and 15(d), not S-K Item 405]

SEGMENT INFORMATION

v3.25.4
SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
The following table presents segment information for the periods presented (in thousands):
Year Ended December 31,
2025 2024 2023
Total Revenues $ 294,282  $ 179,278  $ 116,882 
Less:
Employee related expenses 75,314  69,807  63,429 
Commercial related expenses 25,898  26,996  24,310 
Cost of product sales 19,621  18,647  7,110 
Consultants and third-party services 15,146  15,532  17,942 
Outside clinical trial related expenses 18,307  10,978  9,694 
Other segment items 14,530  13,126  14,888 
Interest expense, net 3,639  5,826  4,600 
(Benefit from) provision for income taxes (245,197) 881  — 
Segment income (loss) $ 367,024  $ 17,485  $ (25,091)
There is no reconciling items or adjustments between segment income (loss) presented above and net income (loss) as presented in our statements of operations. The CODM does not review assets in evaluating the segment results and therefore such information is not presented.
For details of revenues disaggregated by category, see “Note 3 – Revenues”.
Employee related expenses primarily comprised salaries, employee benefits, other employee related expenses and stock-based compensation expense. For details of stock-based compensation expense, see “Note 6 – Stock-Based Compensation.” Other segment items for the periods presented primarily comprised travel related expenses, business insurance, taxes and licenses, and facility related expenses.